References
1. Cancer of the Prostate. Accessed July 17th 2022.
https://seer.cancer.gov/statfacts/html/prost.html
2. Harvey CJ, Pilcher J, Richenberg J, Patel U, Frauscher F.
Applications of transrectal ultrasound in prostate cancer. Br J
Radiol . Nov 2012;85 Spec No 1(Spec Iss 1):S3-17.
doi:10.1259/bjr/56357549
3. Sadeghi-Nejad H, Simmons M, Dakwar G, Dogra V. Controversies in
transrectal ultrasonography and prostate biopsy. Ultrasound Q .
Sep 2006;22(3):169-75. doi:10.1097/01.ruq.0000226875.35184.15
4. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and
survivorship statistics, 2016. C.A. Cancer J Clin . Jul
2016;66(4):271-89. doi:10.3322/caac.21349
5. Alshaikh S, Harb Z. Prostate cancer presenting as huge Mediastinal
and retroperitoneal masses: case report and review of the literature.Case Reports in Pathology . 2017;2017
6. Fitzmaurice C, Allen C, Barber R.M., et al. Global, regional, and
national cancer incidence, mortality, years of life lost, years lived
with disability, and disability-adjusted life-years for 32 cancer
groups, 1990 to 2015: a systematic analysis for the global burden of
disease study. JAMA oncology . 2017;3(4):524-548.
7. Baer J, McGowan P, Pandya S. Prostate cancer metastasis presenting as
isolated mediastinal adenopathy with tracheal invasion. Chest .
2021;160(4):A1300.
8. Teah KM, Bong CP, Mudin K, Soe MZ, Thevarajah S, Yeap BT. Case
report: A rare occurrence of a huge mediastinal mass from disseminated
prostate carcinoma. Annals of Medicine and Surgery . 2021/11/01/
2021;71:102952. doi:https://doi.org/10.1016/j.amsu.2021.102952
9. Smith ZL, Eggener SE, Murphy AB. African-American Prostate Cancer
Disparities. Curr Urol Rep . Aug 14 2017;18(10):81.
doi:10.1007/s11934-017-0724-5
10. Litwin MS, Tan H-J. The diagnosis and treatment of prostate cancer:
a review. Jama . 2017;317(24):2532-2542.
11. Bjurlin MA, Carter HB, Schellhammer P, et al. Optimization of
initial prostate biopsy in clinical practice: sampling, labeling and
specimen processing. The Journal of urology .
2013;189(6):2039-2046.
12. Griffin J, Chen Y, Catto JW, El-Khamisy S. Gene of the month: NKX3.
1. Journal of Clinical Pathology . 2022;75(6):361-364.
13. Gurel B, Ali TZ, Montgomery EA, et al. NKX3.1 as a marker of
prostatic origin in metastatic tumors. Am J Surg Pathol . Aug
2010;34(8):1097-105. doi:10.1097/PAS.0b013e3181e6cbf3
14. Song H, Zhang B, Watson MA, Humphrey PA, Lim H, Milbrandt J. Loss of
Nkx3. 1 leads to the activation of discrete downstream target genes
during prostate tumorigenesis. Oncogene . 2009;28(37):3307-3319.
15. Abeshouse A, Ahn J, Akbani R, et al. The molecular taxonomy of
primary prostate cancer. Cell . 2015;163(4):1011-1025.
16. Oh WJ, Chung AM, Kim JS, et al. Differential immunohistochemical
profiles for distinguishing prostate carcinoma and urothelial carcinoma.Journal of pathology and translational medicine .
2016;50(5):345-354.
17. Gurel B, Ali TZ, Montgomery EA, et al. NKX3. 1 as a marker of
prostatic origin in metastatic tumors. The American journal of
surgical pathology . 2010;34(8):1097.
18. Pitra T, Pivovarcikova K, Alaghehbandan R, et al. Utility of Nkx3. 1
immunohistochemistry in the differential diagnosis of seminal vesicles
versus prostatic tissue in needle biopsy. Annals of Diagnostic
Pathology . 2020;49:151644.
Consent Statement:
Written informed consent was obtained from the patient to publish this
report in accordance with the journal’s patient consent policy
Conflict Of Interest:
There are no conflicts of interest to declare